the patent ownership issue has been explained at g
Post# of 9122
(Total Views: 418)
Posted On: 10/16/2017 6:03:31 PM
the patent ownership issue has been explained at great length many times-patents are put in inventors names-nothing unusual - thats normal-re the flat pack website says NNLX has exclusive usage and the pattern likely repeats w the N-Assay... fiduciary duty enforces the benefit to NNLX
and as I reported from previous financials, the only report of royalty was for $75 out of income of over 100k- the 75 royalty not necessarily to CEO Bret,who had loaned NNLX over 100k, thus signifying his belief in the company
bio tech and mining are the hardest startups and take the longest
as I reported before there's normally a long process of due diligence involving 3 separate groups of people re a patent sale etc re biotechs
and yes I know its been a long time-when a friend recommended this stock to me in 2010 I resisted, saying, "but biotechs take forever', to which he replied, "its already been forever". Thats what happens when an upstart tries to break through the monopoly held by big pharma- the patent sales are an effort to provide the resources to make that breakthrough
Its not very common for such a low penny stock to have revenue-many dont even have a viable product- NNLX has both-and yes its speculative primarily because a primitive species is not primarily motivated by logic, but by power and control through manipulative relationships (e.g.,the relationships formed with buyers by big companies)
and as I reported from previous financials, the only report of royalty was for $75 out of income of over 100k- the 75 royalty not necessarily to CEO Bret,who had loaned NNLX over 100k, thus signifying his belief in the company
bio tech and mining are the hardest startups and take the longest
as I reported before there's normally a long process of due diligence involving 3 separate groups of people re a patent sale etc re biotechs
and yes I know its been a long time-when a friend recommended this stock to me in 2010 I resisted, saying, "but biotechs take forever', to which he replied, "its already been forever". Thats what happens when an upstart tries to break through the monopoly held by big pharma- the patent sales are an effort to provide the resources to make that breakthrough
Its not very common for such a low penny stock to have revenue-many dont even have a viable product- NNLX has both-and yes its speculative primarily because a primitive species is not primarily motivated by logic, but by power and control through manipulative relationships (e.g.,the relationships formed with buyers by big companies)
(6)
(1)Nanologix Inc (NNLX) Stock Research Links
Scroll down for more posts ▼